• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

World Conference on Lung Cancer (WCLC) 2025

September 06 - 09, 2025

  1. Datopotmab deruxtecan
  2. Durvalumab
  3. Osimertinib
  4. Rilvegostomig
  5. Savolitinib
  6. Trastuzumab Deruxtecan
  7. Volrustomig

ppt

Intracranial Efficacy of Datopotamab Deruxtecan (Dato DXd) in Patients With Advanced/metastatic NSCLC in TROPION-Lung01

ppt

Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN

ppt

Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

ppt

Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

pdf

Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT

pdf

Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study

pdf

Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States

ppt

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

ppt

First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

ppt

First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort

ppt

COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib

pdf

A Phase 3, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment of Patients with Metastatic Squamous Non-small-cell Lung Cancer Whose Tumors Express PD-L1

ppt

Rilvegostomig enhances ex vivo immune activation of patient resected NSCLC tumors to greater levels than clinically approved PDx monotherapies or combinations of anti-PD1 and anti-TIGIT bivalent antibodies

ppt

Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs

ppt

SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC

ppt

Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Egfr-TKI Failure: SACHI Study Insights

ppt

Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

pdf

Trastuzumab Deruxtecan in Chinese Patients With Pretreated HER2-mutant Non-small cell Lung Cancer: DESTINY-Lung05 Results

pdf

Trastuzumab Deruxtecan + Pembrolizumab as First-line Treatment in HER2-overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)

pdf

Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer

pdf

Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences